Arthur Franken is a Partner at Gilde Healthcare and is focusing on venture and growth capital investments in the biopharm, medtech, diagnostics and digital health sectors. Since he joined Gilde in 2001, he has made investments in multiple companies including Ablynx (IPO on Euronext), Axonics (IPO on NASDAQ), Breath Therapeutics, Calypso Biotech, Conatus Pharmaceuticals (IPO on NASDAQ), FlowCardia (acquired by C. R. Bard), Levicept, Moximed, MTM Laboratories (acquired by Roche), Pieris (IPO on NASDAQ), ProQR Therapeutics (IPO on NASDAQ), STAT-Dx (acquired by QIAGEN) and uniQure (IPO on NASDAQ).
He represents Gilde on the boards of Breath Therapeutics, Calypso, Levicept and Moximed and served as a board member for FlowCardia, MTM Laboratories, ProQR Therapeutics and STAT-Dx until the trade sales or IPO.
Prior to joining Gilde he was active in cardiovascular research at the Leiden/Amsterdam Center for Drug Research and TNO. He holds a master’s degree in Biopharmaceutical Sciences from Leiden University, the Netherlands. He is a Dutch national.